BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

CVRx (CVRX)CVRxCompany update

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations

Related news

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

MLYSMineralys Therapeutics2026-09-23 20:05 EST

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

TMCITreace Medical Concepts2026-09-15 21:07 EST

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

HYPRHyperfine2026-07-30 12:15 EST

Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care

ANGOAngioDynamics2026-10-02 10:00 EST

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

RYTMRhythm Pharmaceuticals2026-09-10 12:00 EST

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

MLYSMineralys Therapeutics2026-10-01 20:05 EST

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

TMCITreace Medical Concepts2026-09-17 21:16 EST

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

Stock data

Close
1.53 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States